248 related articles for article (PubMed ID: 30568174)
1. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
von Tresckow J; Cramer P; Bahlo J; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Illmer T; Klaproth H; Estenfelder S; Ritgen M; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst BF; Hallek M
Leukemia; 2019 May; 33(5):1161-1172. PubMed ID: 30568174
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
[TBL] [Abstract][Full Text] [Related]
3. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
[TBL] [Abstract][Full Text] [Related]
4. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
von Tresckow J; Cramer P; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Fürstenau M; Illmer T; Klaproth H; Tausch E; Ritgen M; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst BF; Hallek M
Leukemia; 2022 Aug; 36(8):2125-2128. PubMed ID: 35752657
[No Abstract] [Full Text] [Related]
5. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Cramer P; Tresckow JV; Robrecht S; Bahlo J; Fürstenau M; Langerbeins P; Pflug N; Al-Sawaf O; Heinz WJ; Vehling-Kaiser U; Dürig J; Tausch E; Hensel M; Sasse S; Fink AM; Fischer K; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Haematologica; 2021 Feb; 106(2):543-554. PubMed ID: 32107341
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Cramer P; Fürstenau M; Robrecht S; Giza A; Zhang C; Fink AM; Fischer K; Langerbeins P; Al-Sawaf O; Tausch E; Schneider C; Schetelig J; Dreger P; Böttcher S; Kreuzer KA; Schilhabel A; Ritgen M; Brüggemann M; Kneba M; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Haematol; 2022 Oct; 9(10):e745-e755. PubMed ID: 35988545
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Rogers KA; Huang Y; Ruppert AS; Abruzzo LV; Andersen BL; Awan FT; Bhat SA; Dean A; Lucas M; Banks C; Grantier C; Heerema NA; Lozanski G; Maddocks KJ; Valentine TR; Weiss DM; Jones JA; Woyach JA; Byrd JC
J Clin Oncol; 2020 Nov; 38(31):3626-3637. PubMed ID: 32795224
[TBL] [Abstract][Full Text] [Related]
11. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
Leukemia; 2019 Apr; 33(4):969-980. PubMed ID: 30315239
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
13. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M
Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Huber H; Edenhofer S; von Tresckow J; Robrecht S; Zhang C; Tausch E; Schneider C; Bloehdorn J; Fürstenau M; Dreger P; Ritgen M; Illmer T; Illert AL; Dürig J; Böttcher S; Niemann CU; Kneba M; Fink AM; Fischer K; Döhner H; Hallek M; Eichhorst B; Stilgenbauer S
Blood; 2022 Mar; 139(9):1318-1329. PubMed ID: 35108374
[TBL] [Abstract][Full Text] [Related]
17. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.
Stilgenbauer S; Leblond V; Foà R; Böttcher S; Ilhan O; Knauf W; Mikuskova E; Renner C; Tausch E; Woszczyk D; Gresko E; Lundberg L; Moore T; Morris T; Robson S; Bosch F
Leukemia; 2018 Aug; 32(8):1778-1786. PubMed ID: 29749403
[TBL] [Abstract][Full Text] [Related]
18. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Collett L; Howard DR; Munir T; McParland L; Oughton JB; Rawstron AC; Hockaday A; Dimbleby C; Phillips D; McMahon K; Hulme C; Allsup D; Bloor A; Hillmen P
Trials; 2017 Aug; 18(1):387. PubMed ID: 28830517
[TBL] [Abstract][Full Text] [Related]
19. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Cramer P; Tausch E; von Tresckow J; Giza A; Robrecht S; Schneider C; Fürstenau M; Langerbeins P; Al-Sawaf O; Pelzer BW; Fink AM; Fischer K; Wendtner CM; Eichhorst B; Kneba M; Stilgenbauer S; Hallek M
Blood; 2021 Nov; 138(19):1805-1816. PubMed ID: 34086865
[TBL] [Abstract][Full Text] [Related]
20. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Michallet AS; Letestu R; Le Garff-Tavernier M; Aanei C; Ticchioni M; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; De Guibert S; Orsini Piocelle F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan-Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Levy V; Nguyen-Khac F; Feugier P
Blood; 2021 Feb; 137(8):1019-1023. PubMed ID: 33167024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
